Research progress of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
10.13431/j.cnki.immunol.j.20250064
- VernacularTitle:免疫检查点抑制剂治疗肝细胞癌的研究进展
- Author:
Guorui ZHU
1
;
Qinqing YANG
;
Zitong ZHANG
;
Hongjuan ZHANG
;
Shikui GUAN
Author Information
1. 211166,南京医科大学第一临床医学院
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Immunotherapy;
Immune checkpoints;
Immune checkpoint inhibitors;
Programmed cell death protein 1;
Programmed cell death ligand 1;
Cytotoxic T-lymphocyte-associated antigen 4
- From:
Immunological Journal
2025;41(6):440-448
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Tyrosine kinase inhibitors have been used in the mainstream treatment of HCC for many years,but their therapeutic efficacy is limited and the prognosis of patients is very poor.In recent years,the rapid rise of immunotherapy has provided a new direction for tumor treatment.In particular,immune checkpoint inhibitors have shown excellent clinical effect in the treatment of various solid tumors,including HCC.This article reviews various immune checkpoint inhibitors related to HCC and their clinical practice and research progress,aiming to provide a relevant reference and theoretical basis for the immunotherapy of HCC.
